AbbVie Inc. (ABBV) shares are up $2.60 to $56.70 in pre-market trading Friday after the company reported its third-quarter earnings results.
The North Chicago, Illinois-based drugmaker posted earnings of $1.13 per share on revenues of $5.94 billion, up 18.4% from a year ago. Analysts were expecting EPS of $1.08 on revenues of $5.89 billion.
AbbVie said it expects full-year earnings in the range of $4.26 to $4.28 versus consensus of $4.24 per share.
AbbVie shares have lost 14.61% of their value since the beginning of the year, while the S&P’s 500 index has increased 1.5%. The stock has dropped roughly 7% yoy.
Aaron’s, Inc. (AAN) are tanking 22.59% pre-market after the rent-to-own company reported 3Q EPS of $0.39 before the opening bell Friday, compared to the consensus estimate of $0.48. Revenues increased 14.2% from last year to $797.7 million. Analysts expected revenues of $779.66 million.
Aaron’s expects full-year EPS in the range of $2.02 to $2.22 against projections of $2.32/shr.
The stock is currently down $3.64 to $29.91 on 10K shares.
CVS Health Corporation (CVS) dropped $2.80 to $101.00 in pre-market trading after it reported fiscal third-quarter earnings.
The Woonsocket, Rhode Island-based company handed in earnings of $1.29 per share on revenue of $38.64 billion. That compares to Wall Street estimates of $1.29 per share on revenue of $37.90 billion.
For FY15, CVS provided EPS guidance of $5.14-$5.18 versus consensus of $5.16 per share.
Shares of CVS Health were down 3.40%, or $3.53, to $100.27 in pre-market trading on Friday.
Exxon Mobil Corporation (XOM) gained $0.72 to $82.95 in pre-market trading after it reported fiscal results for the third quarter.
In its quarterly report, the producer of crude oil and natural gas said it earned $1.01 per share, well above the $0.90 per share analysts were expecting. Revenue fell 37.1% yoy to $67.34 billion, above views for $63.67 billion. Exxon said earnings of $4.2 billion decreased $3.8 billion, or 47%, from 3Q of 2014.
XOM currently prints a one year loss of 10.22% and a year-to-date loss of around 9%.
The chart below shows where the equity has traded over the last 52 weeks.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!